Key result
Pretreatment with cilostazol reduces myocardial ischemic area ~35% after ischemia-reperfusion injury.
Why the study?
Protecting the myocardium from acute ischemia-reperfusion injuries during open-heart surgeries is vital for improving outcomes, but the effects of cilostazol on myocardial histomorphological changes in this context are unclear.
Does cilostazol reduce myocardial damage in a rat model of ischemia-reperfusion injury?
Does cilostazol reduce myocardial damage in a rat model of ischemia-reperfusion injury?
Absolute Event Rate: 6.94% vs 10.6%
p-value: p=<0.01
Pretreatment with cilostazol significantly reduces myocardial ischemic and necrotic areas in a rat model of ischemia-reperfusion injury.
Supports cilostazol pretreatment in rat ischemia-reperfusion models; leaves open translation to human clinical practice.
Introduction: Protecting the myocardium from acute ischemia-reperfusion (IR) injuries during open-heart surgeries is vital for improving outcomes. This study aimed to compare the effects of cilostazol on the nature and extent of histomorphological changes in the myocardium in a rat IR injury model. Material and Methods: Wistar Albino rats were divided into three groups of eight. The Sham group underwent no coronary occlusion. In the IR group, the left anterior descending artery(LAD) was compressed for 45 minutes to induce acute ischemia, followed by 180 minutes of reperfusion. In the cilostazol group, 20 mg/kg/day cilostazol was administered orally for two weeks before IR induction. Rats were euthanized, and 3 mm myocardial slices were prepared for histomorphological analysis. Changes were assessed at four levels, and total, damaged, and necrotic areas were measured planimetrically. Comparisons were made using Student’s t-test, with P<0.05 considered significant. Results: Pathohistological changes in the IR and cilostazol groups were classified as “mild” in 37.5%/53.1% (P=0.008) and “moderate” in 50.0%/43.8% (P<0.05) respectively. “Severe” changes occurred in 12.5% of IR and 3.1% of cilostazol cases (P=0.006). Ischemic and necrotic areas in the IR group (10.60±1.33 mm² and 5.76±0.62 mm²) were significantly reduced in the cilostazol group (6.94±0.73 mm² and 4.04±0.58 mm², P<<0.01). Conclusion: Cilostazol at 20 mg/kg/day for two weeks before IR injury significantly reduced myocardial ischemic and necrotic areas, showed positive results in histopathological examination demonstrating a strong cardioprotective effect.
No takes yet. Share an insight, caveat, or question.
Amrah et al. (2025) studied Myocardial ischemia-reperfusion injury (n=24). Cilostazol vs. Ischemia-reperfusion without cilostazol was evaluated on Myocardial ischemic area (mm2) (p=<0.01). Cilostazol administered at 20 mg/kg/day for two weeks before ischemia-reperfusion injury significantly reduced myocardial ischemic area compared to control (6.94 vs 10.60 mm2, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: